ADMA BIOLOGICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 69.00% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2021-05-12
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 69.00%, a 11.29% increase year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-03-31 was 62.00%, a 1.64% increase year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-03-31 was 61.00%, a 0.00% change year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-03-31 was 61.00%, a 4.69% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2017 was 57.00%, a 5.56% increase from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2016 was 54.00%.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2014 was 60.00%, a 4.76% decline from fiscal 2013.
- ADMA BIOLOGICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 63.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | 69.00% 10-Q · filed 2021-05-12 | ||||
| 2020-03-31 | 62.00% 10-Q · filed 2021-05-12 | ||||
| 2019-03-31 | 61.00% 10-Q · filed 2020-05-06 | ||||
| 2018-03-31 | 61.00% 10-Q · filed 2019-05-08 | 57.00% 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | 57.00% 10-K · filed 2018-03-29 | ||||
| 2017-03-31 | 64.00% 10-Q · filed 2018-05-14 | ||||
| 2016-12-31 | 54.00% 10-K · filed 2018-03-29 | ||||
| 2016-03-31 | 52.00% 10-Q · filed 2017-05-12 | ||||
| 2014-12-31 | 60.00% 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | 63.00% 10-Q · filed 2015-11-10 | ||||
| 2014-06-30 | 63.00% 10-Q · filed 2015-08-11 | ||||
| 2014-03-31 | 63.00% 10-Q · filed 2015-05-12 | ||||
| 2013-12-31 | 63.00% 10-K · filed 2015-03-09 | ||||
| 2013-09-30 | 63.00% 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | 63.00% 10-Q · filed 2014-08-11 | ||||
| 2012-06-30 | 82.00% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |